Clinical JAK2 V617F mutation testing: Limited utility for general hospital patients with venous and arterial thromboses in common locations

American Journal of Hematology

Volumn 83, Issue 6, 2008, Pages 519-520

  Abel, Gregory A ^a   DeAngelo, Daniel J ^a   Connors, Jean M ^b   Sholl, Lynette M ^b   McCaffrey, Ronald P ^b   Longtine, Janina A ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; HOMOCYSTEINE; PHOSPHOLIPID ANTIBODY; PROTHROMBIN; JANUS KINASE 2;

ANTITHROMBIN III DEFICIENCY; DEEP VEIN THROMBOSIS; GENE; GENE MUTATION; HUMAN; JAK2V617F GENE; LETTER; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MESENTERIC VEIN THROMBOSIS; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RETROSPECTIVE STUDY; RISK FACTOR; STROKE; THROMBOCYTHEMIA; VENOUS THROMBOEMBOLISM; ADULT; FEMALE; GENERAL HOSPITAL; GENETICS; MALE; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; THROMBOSIS;

ADULT; DNA MUTATIONAL ANALYSIS; FEMALE; HOSPITALS, GENERAL; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOSIS;

EID: 44349133258     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21159     Document Type: Letter

References (6)

1. Colaizzo D, Amitrano L, Tiscia GL, et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 2007;5:55-61.
2. Patel RK, Lea NC, Heneghan MA, et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 2006;130:2031-2038.
3. Remacha AF, Estivill C, Sarda MP, et al. The V617F mutation of JAK2 is very uncommon in patients with thrombosis. Haematologica 2007;92:285-286.
4. Pardanani A, Lasho TL, Schwager S, et al. JAK2V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder. Leukemia 2007;21:1828-1829.
5. Pardanani A, Lasho TL, Morice WG, et al. JAK2V617F is infrequently associated with arterial stroke in the absence of overt myeloproliferative disorder. J Thromb Haemost 2007;5:1784-1785.
6. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005;106:2162-2168.